Related Experiment Video
Updated: Dec 23, 2025
08:49
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
9.4K
A Novel Inhibition Modality for Phosphodiesterase 2A
Kosuke Nakashima1, Hideki Matsui1
1Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa-shi, Kanagawa, Japan.
SLAS Discovery : Advancing Life Sciences R & D
|April 29, 2020
Summary
Researchers discovered novel phosphodiesterase type 2A (PDE2A) inhibitors that maintain efficacy in low cyclic GMP conditions, offering new therapeutic potential for cognitive disorders.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Phosphodiesterase type 2A (PDE2A) is a key regulator of cyclic nucleotide signaling.
- PDE2A's dual-substrate activity (cGMP and cAMP) and cGMP-dependent activation present complex modulation challenges.
- Targeting PDE2A is of interest for treating central nervous system diseases impacting memory and cognition.
Purpose of the Study:
- To discover small molecules with a novel PDE2A inhibition mechanism.
- To investigate the impact of cGMP concentration on PDE2A inhibitor efficacy.
- To identify PDE2A inhibitors that overcome cGMP-dependent feedback inhibition.
Main Methods:
- Assessed inhibitory effects of previously reported and newly identified PDE2A inhibitors.
- Evaluated inhibitor performance across different cyclic guanosine monophosphate (cGMP) concentrations (70 nM and 4 μM).
- Investigated the role of PDE2A's GAF domains in inhibitor response.
Main Results:
- Previously reported PDE2A inhibitors showed reduced efficacy at lower cGMP concentrations (70 nM) due to GAF domain-mediated feedback.
- Newly identified PDE2A inhibitors maintained strong inhibitory effects at both low (70 nM) and high (4 μM) cGMP concentrations.
- This lack of cGMP-dependent impairment suggests a distinct inhibition modality.
Conclusions:
- Novel PDE2A inhibitors exhibit consistent efficacy irrespective of physiological cGMP levels.
- These inhibitors may be more effective in treating neurological conditions characterized by lower cGMP concentrations.
- The findings offer a promising new class of therapeutics for cognitive enhancement and CNS disorders.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
433
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
433
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.4K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.4K
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
830
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
830
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
01:30Enzyme Inhibition
90.3K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
90.3K
01:28Depolarizing Blockers: Mechanism of Action
2.5K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
2.5K